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The p28 and p65 proteins of mouse hepatitis virus (MHV) are the most amino-terminal protein domains of
the replicase polyprotein. Cleavage between p28 and p65 has been shown to occur in vitro at cleavage site 1
(CS1), 247Gly2Val248, in the polyprotein. Although critical residues for CS1 cleavage have been mapped in vitro,
the requirements for cleavage have not been studied in infected cells. To define the determinants of CS1
cleavage and the role of processing at this site during MHV replication, mutations and deletions were
engineered in the replicase polyprotein at CS1. Mutations predicted to allow cleavage at CS1 yielded viable
virus that grew to wild-type MHV titers and showed normal expression and processing of p28 and p65. Mutant
viruses containing predicted noncleaving mutations or a CS1 deletion were also viable but demonstrated
delayed growth kinetics, reduced peak titers, decreased RNA synthesis, and small plaques compared to
wild-type controls. No p28 or p65 was detected in cells infected with predicted noncleaving CS1 mutants or the
CS1 deletion mutant; however, a new protein of 93 kDa was detected. All introduced mutations and the deletion
were retained during repeated virus passages in culture, and no phenotypic reversion was observed. The results
of this study demonstrate that cleavage between p28 and p65 at CS1 is not required for MHV replication.
However, proteolytic separation of p28 from p65 is necessary for optimal RNA synthesis and virus growth,
suggesting important roles for these proteins in the formation or function of viral replication complexes.
Two families of large positive-strand RNA viruses, the ar-
teriviruses and the coronaviruses, belong to the order Nidovi-
rales. Despite differences in the genome sizes of the arterivi-
ruses (13 to 16 kb) and coronaviruses (27 to 32 kb), these virus
families have several important features in common, including
a polycistronic genome, an array of conserved protein do-
mains, and a discontinuous RNA transcription strategy. An-
other important conserved feature of nidovirus replication is
the expression of viral replicase proteins from large polypro-
tein precursors. These replicase polyproteins are cleaved co-
and posttranslationally by virus-encoded proteinases to yield
up to 15 mature replicase protein products. Along with puta-
tive cellular factors, the mature replicase proteins and precur-
sors are thought to mediate all stages of viral RNA synthesis on
membrane-bound viral replication complexes in the cytoplasm.
Previous studies have demonstrated roles for arterivirus repli-
case proteins in the formation and function of viral replication
complexes (17, 21, 22, 26). However, the functions of the ma-
jority of coronavirus replicase proteins during viral replication
have not been determined.
The coronavirus replicase gene (gene 1) is composed of two
overlapping open reading frames (ORF1a and ORF1b) that
are translated by host cell ribosomes to produce the replicase
polyproteins. Translation of ORF1a yields a polyprotein of
nearly 490 kDa, while a 1 ribosomal frameshift allows trans-
lation of an ORF1a-ORF1b fusion polyprotein that is approx-
imately 800 kDa. Cleavage of the coronavirus replicase
polyproteins is mediated by one or two papain-like cysteine
proteinases (PLP1 and PLP2) and a picornavirus 3C-like cys-
teine proteinase (3CLpro) to yield 12 to 16 mature replicase
protein products. 3CLpro cleavage sites have been identified at
conserved regions in all coronaviruses, including the newly
discovered coronavirus associated with severe acute respira-
tory syndrome (SARS-CoV) (23, 26). In contrast, the conser-
vation and activity of PLP1 and PLP2 domains vary among the
three known coronavirus serogroups (groups 1, 2, and 3). The
group 1 and 2 coronaviruses express both PLP1 and PLP2
activities and have in common the feature that PLP1 cleaves
the first two amino-terminal products from the polyproteins
(26). Specifically, viruses in group 1, such as human coronavi-
rus 229E, liberate an amino-terminal 9-kDa protein and an
87-kDa protein after PLP1-mediated processing (12, 27). For
group 2 coronaviruses, including bovine coronavirus and
mouse hepatitis virus (MHV), PLP1 has been shown in vitro to
cleave an amino-terminal 28-kDa protein and a 65-kDa pro-
tein, referred to as p28 and p65, respectively (Fig. 1) (1, 2, 7, 8,
10, 14). In contrast, SARS-CoV, as well as the avian corona-
viruses (group 3), such as infectious bronchitis virus (IBV),
only express active PLP2, which is responsible for cleavage of
amino-terminal proteins (23, 26). These observations suggest
that PLP1-mediated cleavages may not be essential for coro-
navirus replication or that the amino-terminal proteins liber-
ated by PLP1s have group-specific functions during replication.
MHV has been extensively used as a model for studies of
coronavirus replicase protein expression and processing. The
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determinants of MHV PLP1-mediated cleavages have been
studied in detail by using in vitro expression and processing
assays (2, 3, 10, 14). PLP1 has been shown to proteolytically
process the first two cleavage sites in the MHV replicase
polyprotein: between p28 and p65 at 247G2V248 (referred to as
cleavage site 1, or CS1, in this report) and between p65 and
p210 at 832A2G833 (CS2) (3, 10, 14). Until recently, the lack of
a reverse genetics system has hindered the characterization of
these cleavage sites in the context of MHV infection. Several
lines of evidence indicate that continuous translation and pro-
cessing of the MHV replicase polyprotein are required for
virus replication (15, 18, 19). However, the requirements for
processing at specific cleavage sites in the polyprotein, such as
between p28 and p65, have not been shown. Biochemical ex-
periments determined that both p28 and p65 are associated
with intracellular membranes (4, 11, 20), and confocal immu-
nofluorescence microscopy data have shown that both p28 and
p65 localize to viral replication complexes in punctate perinu-
clear foci (20; S. M. Brockway, X. T. Lu, T. R. Peters, T. S.
Dermody, and M. R. Denison, submitted for publication).
These results suggest that p28 and p65 may play a role in
replication complex formation or RNA synthesis.
In the present study, we used a reverse genetics approach to
verify the critical CS1 residues necessary for cleavage and to
determine if cleavage of p28 from p65 is required for MHV
replication. By using the MHV strain A59 infectious clone,
viruses were generated that had either predicted cleaving or
noncleaving mutations in CS1. Viruses with predicted non-
cleaving CS1 mutations were viable but were unable to process
p28 and p65, instead expressing an uncleaved p93 precursor
protein. Although noncleaving CS1 mutants were able to rep-
licate, these viruses had diminished peak titers, smaller
plaques, and decreased RNA synthesis compared with wild-
type virus and cleaving CS1 mutant viruses. Despite the defect
in viral replication, the mutant viruses did not demonstrate
phenotypic reversion or changes at introduced mutations after
repeated passage in culture. This study demonstrates that
while cleavage of p28 from p65 is not required for viral repli-
cation, alterations at the first cleavage site alter virus growth,
protein processing, and RNA synthesis.
MATERIALS AND METHODS
Wild-type virus, cells, and antibodies. MHV strain A59 was used as the
wild-type control in all experiments. Delayed brain tumor (DBT) cells (13) and
baby hamster kidney cells expressing the MHV receptor (BHK-MHVR) (5, 6)
were grown in Dulbecco’s modified Eagle medium that contained 10% fetal calf
serum for all experiments. Media of BHK-MHVR cells were supplemented with
G418 (0.8 mg/ml) for selection of cells expressing the receptor. Polyclonal anti-
sera UP102 (anti-p28 and -p65) and -p22, used for biochemical experiments,
have been previously described (8, 16) (Fig. 1).
Construction of mutagenized A59 infectious-clone fragment A plasmids. Site-
directed mutations were made in the p28-p65 cleavage site (CS1) by PCR with
the primers shown in Table 1. For all reactions, A59 infectious-clone cDNA
fragment A construct pCR-XL-TopoA, which consists of nucleotides (nt) 1 to
4882, was used as template DNA (25). Primer-generated restriction sites (5
AflII and 3 BstZ17I) were used to clone PCR products into pCR-XL-TopoA in
place of wild-type CS1.
Generation of CS1 mutant viruses. Viruses containing the PCR-generated
mutations at CS1 were produced by the infectious-clone strategy for A59 de-
scribed by Yount et al. (25). Briefly, plasmids containing the cDNA cassettes of
the MHV genome were digested with MluI and BsmBI for fragment A; BglI and
BsmBI for fragments B and C; BsmBI for fragments D, E, and F; and SfiI and
BsmBI for fragment G. Digested, gel-purified fragments were ligated together in
FIG. 1. A59 genome organization and replicase antibodies. The A59 genome is 32 kb long. The replicase gene (gene 1, 22 kb) is shown, with
replicase protein domains in overlapping ORF1a and ORF1b. Hatched boxes indicate proteinases: PLP1 domain (papain-like proteinase 1), PLP2
domain (papain-like proteinase 2), and 3CLpro (3C-like proteinase). The protein domains for mature proteins p28, p65, p210, p22, Pol, and Hel
are indicated. Arrows beneath proteins indicate cleavage by the relevant proteinases. The first cleavage site between p28 and p65 (CS1) is shown.
Black rectangles beneath the schematic indicate proteins generated to induce the rabbit polyclonal antibodies used in this study.










a Underlining indicates mutated or deleted nucleotides.
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a total reaction volume of 200 l overnight at 16°C. Following chloroform
extraction and isopropanol precipitation of ligated DNA, full-length transcripts
of MHV infectious-clone cDNA were generated in vitro with the mMessage
mMachine T7 Transcription Kit (Ambion) in accordance with the manufactur-
er’s protocol with modifications. Fifty-microliter reaction mixtures were supple-
mented with 7.5 l of 30 mM GTP, and transcription was performed at 40.5°C for
25 min, 37.5°C for 50 min, and 40.5°C for 25 min. In parallel, transcripts encoding
the MHV nucleocapsid protein (N) were generated in vitro with N cDNA
generated by PCR (25). N transcripts and MHV infectious-clone transcripts were
then mixed and electroporated into BHK-MHVR cells. Briefly, BHK-MHVR
cells were grown to subconfluence, trypsinized, washed twice with phosphate-
buffered saline (PBS), and then resuspended in PBS at a concentration of 107/ml.
Eight hundred microliters of cells was then added to RNA transcripts in an
electroporation cuvette with a 4-mm gap, and three electrical pulses of 850 V at
25 F were delivered with a Bio-Rad Gene Pulser II electroporator. Transfected
cells were then laid over a layer of 106 uninfected DBT cells in a 75-cm2 flask and
incubated at 37°C for 30 h. Virus viability was determined by syncytium forma-
tion, and progeny were passaged and purified by plaque assay.
Viral passages, RT-PCR, and sequencing of viral RNA. Viable viruses were
plaque purified and then successively passaged 10 times at either 8- or 18-h
intervals on DBT cells. After 10 passages, cell supernatant was harvested and
centrifuged for 10 min at 700  g at 4°C to clear cell debris. Clarified supernatant
was then centrifuged at 150,000  g for 90 min at 4°C to pellet virus. The virus
pellet was then lysed with Tri-Reagent (Sigma), and viral RNA was isolated in
accordance with the manufacturer’s protocol. To generate viral cDNA corre-
sponding to the first 5 kb of the genome, reverse transcription (RT)-PCR was
performed. An antisense primer complementary to nt 5500 through 5531 of the
MHV genome was used for reverse transcription. The RT product was then
amplified by PCR with primers corresponding to nt 200 through 230 (sense) and
5500 through 5531 (antisense). Initial isolates at passage 2 (P2) were sequenced
across 600 nt spanning the cleavage site coding region with an ABI Prism
automated sequencer to confirm the introduced mutations. Passage 10 (P10)
viruses were sequenced from nt 230 through nt 5500 to determine maintenance
of mutations and any additional changes during passage in p28, p65, and PLP1.
Protein expression and immunoprecipitations. Immunoprecipitations, pulse-
labeling, and pulse-chase translation experiments were performed as previously
described (7, 8).
Viral growth assays and metabolic labeling of viral RNA. Mutant viruses were
purified and analyzed by viral growth and RNA synthesis assays. For viral growth
determination, DBT cells were infected at a multiplicity of infection (MOI) of
either 0.1 or 5 PFU/cell. Aliquots of medium were collected from 2 h to 48 h
postinfection (hpi), and titers were determined by plaque assay as described
previously (15). For metabolic labeling of viral RNA, DBT cell monolayers
(approximately 3  106 cells) were either mock infected or infected at an MOI
of 5 PFU/ml. At 4.5 hpi, actinomycin D (Sigma) was added to the cells at a final
concentration of 20 g/ml. Cells were labeled with 100 Ci of [3H]uridine/ml in
the presence of actinomycin D from 5 to 7 hpi. For harvesting of viral RNA, cells
were washed twice with PBS and then lysed with 500 l of cell lysis buffer (150
mM NaCl, 1% NP-40, 0.5% deoxycholate, 50 mM Tris [pH 8.0]). Lysates were
centrifuged at 3,500  g to remove nuclei, and then RNA in 200 l of post-
nuclear supernatant was precipitated with trichloroacetic acid (TCA). Precipi-
tated RNA was dried onto glass microfiber filters (Whatman) by vacuum filtra-
tion, and radioactivity was measured in a liquid scintillation counter (Beckman).
Northern blot analysis. DBT cells were mock infected or infected at an MOI
of 5 PFU/cell with wild-type or CS1 mutant virus. Cells were lysed at 10 hpi with
Trizol (Invitrogen), and RNA was isolated in accordance with the manufacturer’s
protocol. RNA from approximately 4  105 cells was electrophoresed in a 0.8%
agarose-formaldehyde gel at 144 V for 4 h. For Northern blot analysis, RNA was
transferred overnight onto a nylon membrane (HyBond N; Amersham Bio-
sciences) with a wick transfer system. RNA was UV cross-linked to the nylon
membrane and probed with a 32P-labeled probe complementary to the 3 un-
translated region (UTR) as described previously (24). RNA was visualized by
autoradiography, and images were prepared with Adobe Photoshop 7.0 (Adobe).
RESULTS
Recovery, sequencing, and stability of A59 CS1 mutants. To
determine if cleavage between p28 and p65 at CS1 is required
for virus growth, mutations were introduced at P2, P1, and P1
of CS1, which were shown to either allow or abolish cleavage
in vitro (10, 14) (Fig. 2). Mutated fragment A cDNAs were
used to assemble full-length MHV genomic cDNA, which was
transcribed in vitro to yield mutant MHV genomic RNA.
BHK-MHVR cells were electroporated with in vitro-tran-
scribed genome RNA and monitored for MHV-induced syn-
cytium formation. Viral syncytia were detected within 24 h in
cells electroporated with full-length wild-type genome RNA
(icwt) and with genome RNA containing mutations that were
predicted to allow cleavage at CS1 (mut8 and mut9) (Fig. 2).
Unexpectedly, viral syncytia were also detected in cells elec-
troporated with RNA containing predicted noncleaving CS1
mutations (mut3, mut4, and mut5). However, a delay in the
timing and extent of the viral cytopathic effect (CPE) was
noted during initial recovery of virus from electroporated cells
producing predicted CS1 noncleaving mutant viruses. To verify
the retention of the introduced mutations, both supernatant
virus populations of P2 and plaque-purified virus clones from
P2 of each mutant (P2 clone 1 [P2C1]) were sequenced across
nucleotides encoding CS1. All viruses, including those pre-
dicted to be noncleaving, were found to have the correct CS1
nucleotide sequence, and no additional nucleotide changes
were noted in the 300 nt flanking each side of CS1. Compar-
ison of the sequence of the P2 population virus with the P2C1
cloned viruses demonstrated no heterogeneity or changes at
any of the sequenced nucleotides (data not shown). These re-
sults demonstrated that mutations at CS1 predicted to either re-
tain or abolish cleavage at CS1 allowed recovery of viable virus.
To determine if the CS1 mutations were stable over multiple
passages, stocks from cloned mutant viruses (P2C1) were pas-
FIG. 2. Mutagenesis of CS1. (Top) Organization and relative sizes
of cDNA fragments A to G used for assembly of full-length MHV
cDNA. (Middle) Expansion of genome fragment A showing coding
domains for p28, p65, and the N-terminal 33% of p210, with the PLP1
domain intact. The amino acid (aa) and nucleotide termini of fragment
A are indicated. (Bottom) P5 through P5 of CS1 indicated by position
and nucleotide and amino acid sequences, with amino acid numbering
for P1 and P1. The vertical arrow shows the site of cleavage. Nucle-
otide and amino acid mutations are shown for each mutant, and the
deletion is indicated by the caret. Cleavage in vitro is based on previ-
ously published studies (10, 14), and virus viability is based on data
from this study. N/T, not tested in vitro.
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saged 10 times in DBT cells at 8- to 18-h intervals, depending
on the earliest appearance of CPE, to attempt to drive a
reversion event. During passage in culture, the CS1 predicted
noncleaving mutants demonstrated no change in the timing or
extent of CPE in comparison with that originally observed
in the electroporated culture. mut3, mut4, and mut5 demon-
strated a visibly reduced plaque size, an extended time to the
first detection of plaques (30 versus 24 hpi), and a reduction in
the plaque area of 53 to 77% at 30 h, with the plaques never
achieving the area of the wild-type virus (Fig. 3A). Even after
10 passages in cell culture, CS1 predicted noncleaving mutants
retained their small plaque size, with no heterogeneity of
plaque size observed. At the conclusion of passage 10 (P2C1-
10) for each mutant, RNA was isolated from supernatant virus
and sequenced across the first 5 kb of gene 1 (nt 230 through
5500). Sequence analysis of the P2C1-10 populations for each
mutant demonstrated that all CS1 mutations were retained
(Fig. 3B), and no additional changes were noted within p28,
p65, or PLP1. In the present study, we did not sequence the
entire 32-kb genomes of the original eight input viruses and the
P2C1-10 viruses. Therefore, we cannot entirely exclude the
possibility that compensatory second-site mutations occurred
during virus passage. However, the lack of mutations in the
first 5 kb of gene 1 (p28, p65, and PLP1 coding regions), as
well as the complete retention of the wild-type and mutant
virus phenotypes, supports the conclusion that CS1 mutant
viruses were genetically stable following multiple passages in
cell culture.
Reduced peak titers of predicted noncleaving CS1 mutants.
Viral growth experiments were performed to determine if CS1
predicted noncleaving mutants had defects in virus replication
compared to predicted cleaving and wild-type controls (Fig. 4).
DBT cell monolayers were infected at MOIs of 0.001, 0.1, and
5 PFU/cell; supernatant virus was harvested at various times
from 2 to 24 hpi; and viral titers were determined by plaque
assay. Infections at MOIs of 0.1 and 5 PFU/cell both demon-
strated consistent single-cycle growth kinetics (Fig. 4B). Be-
cause of this consistency and the difficulty of producing higher-
titer stocks of the predicted noncleaving mutants, an MOI of
0.1 PFU/cell was chosen for subsequent experiments.
During single-cycle growth experiments, wild-type A59 and
assembled wild-type MHV (icwt), as well as predicted cleaving
mutants (mut8 and mut9), had peak viral titers of 2  107 to
5  107 PFU/ml (Fig. 4A). In contrast, predicted noncleav-
ing mutants (mut3, mut4, and mut5) had peak viral titers of
1  106 to 3  106 PFU/ml, consistently 0.5 to 1.5 logs less than
the wild type and the predicted cleaving mutants. Interestingly,
predicted cleaving mutant mut8 showed lower titers at 12 h but
achieved wild-type titers by 24 h, while the predicted noncleav-
ing mutants never attained wild-type titers (Fig. 4A). On re-
FIG. 3. Plaque morphology and sequences of CS1 mutants. (A) Plaque morphology of CS1 mutants. All images were obtained at the same
resolution (magnification, 10) with a Zeiss Axiovert microscope. Black circles were visually drawn at limits of plaques. Percentages represent total
plaque areas of black circles, with A59 arbitrarily set at 100%. icwt is assembled wild-type strain A59; the other viruses are mutants as in Fig. 2.
(B) Sequence data from RT-PCR of virion RNA showing retained mutations following passage of cloned wild-type and mutant viruses in culture
as described in the text. The location of CS1 is indicated by RGV and a vertical dotted line. Mutations are indicated by horizontal bars with dots
at mutated nucleotides and the resulting amino acid change underneath the bar.  indicates a nucleotide deleted in mutCS1.
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peat experiments, mut8 and mut9 occasionally showed this
intermediate growth phenotype.
To determine if there was a direct difference in mutant virus
growth at a higher MOI, A59 and putative noncleaving mutant
mut5 were directly compared for growth in culture following
infections at MOIs of 0.1 and 5 PFU/cell (Fig. 4B). At an MOI
of 0.1 PFU/cell, wild-type A59 had a peak titer of 2  107 PFU/
ml while mut5 had a peak titer of 9  105 PFU/ml, consistent
with the experiment in Fig. 4A. When the MOI was increased
50-fold to 5 PFU/cell, A59 had a peak titer of 3  107 PFU/ml
while mut5 had a peak titer of 6  106 PFU/ml. A similar result
was seen with an MOI of 0.001, where even with delayed
growth kinetics, mut5 never achieved wild-type titers (data not
shown). Thus, there was a clear viral growth defect in the pre-
dicted noncleaving mutants compared with the wild type and
the predicted CS1 cleaving mutants.
Cleavage at CS1 is abolished by mutations at residues P2
and P1. To determine if CS1 mutants were capable of cleaving
p28 from p65 in the replicase polyprotein, immunoprecipita-
tion assays were performed. DBT cells were either mock in-
fected or infected with A59, icwt, or the CS1 mutants and
labeled with [35S]Met-Cys from 6 to 7 hpi. Cytoplasmic extracts
were prepared and immunoprecipitated with antiserum di-
rected against p28 and p65 (UP102) (Fig. 5). The predicted
CS1-cleaving mutants, mut8 and mut9, demonstrated patterns
of protein expression and processing identical to those of A59
and icwt, with distinct p28 and p65 proteins detected (Fig. 5A).
In cells infected with the predicted noncleaving mutants, mut3,
mut4, and mut5, the pattern of detected proteins was quite
different, with no p28 or p65 detected following 1 h of labeling.
A much less prominent protein band with a mobility of ap-
proximately 28 kDa was detected in the mut3-, mut4-, and
mut5-infected lysates; however, it also was detected in mock-
infected cells by immune serum in infected cells and by pre-
immune serum (data not shown), indicating that it was a comi-
grating, nonspecifically precipitated product. A new, discrete
band of 93 kDa was immunoprecipitated only in mut3-, mut4-,
and mut5-infected cells by immune serum. This 93-kDa protein
was consistent with the size of a putative uncleaved p28-p65
precursor. We also observed several heterogeneous bands of
label, most prominently one of approximately 70 kDa that was
unique to cells infected with the noncleaving mutants (Fig. 5A).
This 70-kDa protein could not be accounted for by putative
uncleaved precursors. While additional studies are required to
identify this protein and its source, possibilities include alter-
nate folding or degradation of p93, oligomerization, or alter-
native cleavage in the p28 or p65 protein (see Discussion).
To determine if any delayed processing at CS1 was occurring
during infection with mut3, mut4, and mut5, pulse-chase ex-
periments were performed. Infected DBT cells were labeled
for 60 min at 6 hpi and followed by a chase with excess unla-
beled Met-Cys for an additional 90 min (Fig. 5B). p28 and p65
were readily detectable at 60 min in cells infected with icwt but
not in cells infected with noncleaving mutants. Even following
the additional 90-min chase, there was no disappearance of
p93 linked to the concomitant appearance of p28 and p65 in
noncleaving mutants, supporting the conclusion that process-
ing did not occur at CS1 in the noncleaving mutants. Together,
the label and chase experiments demonstrated that P2-R246
and P1-G247 are critical residues for CS1 cleavage during rep-
licase polyprotein expression and processing in infected cells,
while P1-V248 could be replaced with both conservative (Ala)
and nonconservative (His) residues and still allow cleavage at
CS1. The results were consistent with the previous in vitro
analyses (10, 14). The finding that replication occurred in the
presence of the P1 substitutions was interesting, but what was
remarkable was that even P2 and P1 mutations that appeared
to abolish cleavage at CS1 allowed recovery of viable virus.
Thus, these results suggest that cleavage of p28 from p65 is not
required for virus viability; however, the absence of CS1 pro-
cessing was associated with impairment of virus growth.
Deletion of CS1 P2-P1 RGV allows recovery of viable virus.
To confirm that MHV was capable of replicating in the ab-
FIG. 4. Growth of CS1 mutant viruses in DBT cells. (A) Growth of
CS1 mutants at an MOI of 0.1 PFU/cell. A59, icwt, and mutant viruses
mut8, mut9, mut3, mut4, and mut5 were used to infect DBT cells at an
MOI of 0.1 PFU/ml. Following 30 min of attachment, cells were rinsed
three times and incubated in medium. Samples were obtained at the
postinfection (p.i.) times indicated, and titers were determined by
plaque assay on DBT cells at 37°C. Error bars indicate standard devi-
ations of plaque assay replicates. (B) Comparison of growth at low and
high MOIs. A59 and mut5 viruses were used to infect DBT cells at
MOIs of 5 and 0.1 PFU/ml. Virus growth assay was performed as de-
scribed for panel A, with samples taken at the postinfection times
indicated and titers determined by plaque assay. The values shown are
averages of duplicate plaque assays.
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sence of CS1 cleavage, we generated mutant viruses that
contained an in-frame 9-nt deletion of residues 246RGV248
at CS1 (mutCS1) (Fig. 2 and 3). Following electroporation
of mutCS1 transcripts into BHK-MHVR cells, CPE was ob-
served that was identical to that caused by mut5, with delayed
appearance of CPE and small, plaque-like foci of infection
with limited distal spread. During plaque purification, plaques
were delayed in growth and reduced in size. Stocks were ob-
tained for sequencing, and the virus was passaged as with the
point mutations. Sequencing confirmed the in-frame 9-nt de-
letion in the recovered virus, and no additional changes, inser-
tions, or deletions were noted across the first 5 kb of the
genome following 10 passages (Fig. 3).
The mutCS1 virus was compared with A59, icwt, cleaving
mut9, and noncleaving mut5 for virus growth and protein ex-
pression (Fig. 6). When mutCS1 was directly compared for
virus growth with wt, icwt, cleaving mut9, and noncleaving
mut9, mutCS1 was identical to noncleaving mut5 in growth
kinetics (Fig. 6A). Peak titers of mutCS1 and mut5 were
5.5  106 to 6  106 PFU/ml, in comparison with peak titers of
2  107 to 4  107 for A59, icwt, and cleaving mut9, completely
consistent with experiments in Fig. 4 in demonstrating a 0.5-log
reduction in peak titers and a lack of the ability to achieve
wild-type titers at any point during infection.
When infected cells were analyzed for protein expression
and CS1 cleavage, mutCS1 had the same pattern of proteins
as mut5, with no detectable p28 or p65 and with detection of
the novel 93-kDa protein and the less prominent, heteroge-
neous 70-kDa protein (Fig. 6B). Both virus viability and de-
tection of the 93-kDa protein strongly suggested that PLP1,
PLP2, and 3CLpro activities and cleavage were intact and
unaffected by CS1 mutations. To determine the activity of
3CLpro at downstream cleavage sites, cell lysates for all viruses
were probed for p22, a well-characterized protein known to be
cleaved by 3CLpro (Fig. 6C). p22 was readily and equivalently
detected in A59, icwt, cleaving mut9, and noncleaving mut5 and
mutCS1, demonstrating intact 3CLpro function and cleavage
at known sites. Thus, by growth and protein expression and
processing, mutCS1 behaved identically to the noncleaving
point mutant, mut5. The recovery and growth of mutCS1
further confirmed the lack of CS1 cleavage of mut3, mut4, and
mut5 by demonstrating the ability of MHV to replicate in the
absence of the three-amino-acid RGV core CS1 cleavage site.
Further, the viability of mutCS1 demonstrated that amino
acids, specifically, the three-residue cleavage site, could be de-
leted from the polyprotein and still permit virus growth.
Diminished viral RNA synthesis with noncleaving CS1 mu-
tant viruses. Inhibition of MHV replicase polyprotein process-
ing by proteinase inhibitors leads to rapid shutoff of viral RNA
synthesis (15). To determine if inhibition of CS1 cleavage af-
fects viral RNA synthesis, DBT cells were either mock infected
or infected with the wild type or the CS1 virus mutants at an
MOI of 5 PFU/cell. Cells were metabolically labeled with 100
Ci of [3H]uridine/ml in the presence of actinomycin D from
5 to 7 hpi, and TCA-precipitable RNA was measured by liquid
scintillation (Fig. 7A). All CS1-cleaving viruses (A59, icwt,
mut8, and mut9) had equivalent amounts of incorporation of
label into viral RNA in comparison with the background mea-
surement in the mock-infected, actinomycin D-treated cells.
In contrast, noncleaving mutants (mut3, mut4, mut5, and
mutCS1) had significantly decreased total RNA synthesis,
from 50 to 75% reduced compared to the wild type and the
cleaving mutants. While there was some variability in the pre-
cise amount of incorporation between different noncleaving
mutants in replicates of the experiment (data not shown), the
noncleaving mutants were significantly reduced in total RNA
synthesis in every experiment.
Having demonstrated an inhibition of viral RNA synthesis
FIG. 5. Processing of p28 and p65 in CS1 mutants. (A) Pulse-labeling of replicase proteins p28 and p65. DBT cells were infected for 6 h and
labeled with [35S]Met-Cys for 60 min, and lysates of infected cells were immunoprecipitated with UP102, followed by electrophoresis in sodium
dodecyl sulfate–5 to 18% polyacrylamide gels. Molecular mass (kilodaltons) markers are to the left of the gel; A59, icwt, and mutant viruses are
indicated above the lanes; and masses of specific proteins (in kilodaltons) are shown to the right of the gel, with p28 and p65 also indicated by filled
circles. The novel 93- and 70-kDa products are indicated by arrows. (B) Pulse-chase labeling. The experiment was performed the same way as the
pulse-labeling experiment, except that following the 60-min labeling period (indicated by the number 60 above lanes), the radiolabel was removed
and cells were incubated in medium with excess unlabeled Met-Cys for an additional 90-min chase (c90). Viruses, markers, and proteins are the
same as in panel A.
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with the noncleaving CS1 mutants, we next sought to deter-
mine if these viruses exhibit specific defects in genome repli-
cation or subgenomic RNA (sgRNA) synthesis. DBT cells
were mock infected or infected at an MOI of 5 PFU/cell. At 10
hpi, total cellular RNA was harvested and probed by Northern
blot assay with a radiolabeled probe complementary to the 3
UTR to detect all MHV positive-strand full-length genomic
RNA and sgRNA (Fig. 7B). All seven species of viral RNA
were detected for all viruses, both cleaving and noncleaving.
The CS1-noncleaving viruses exhibited reduced levels of both
full-length genome RNA and sgRNA species compared with
A59, icwt, and the CS1-cleaving mutants; however, the mea-
sured ratios of genomic RNA to sgRNA were the same for the
wild type and the cleaving and noncleaving mutants (data not
shown). These results indicate that the global reduction in
RNA synthesis measured in Fig. 7A was due to overall reduc-
tion in RNA synthesis rather than inhibition of either tran-
scription of sgRNAs or replication of genomic RNA alone.
DISCUSSION
Proteolytic cleavage of p28 and p65 at CS1 is not required
for, but enhances, viral replication. In the present study, we
determined that cleavage of p28 from p65 is not necessary for
MHV replication; however, abolition of cleavage resulted in a
global reduction in all species of viral RNA, with an associated
reduction in viral growth and spread. The fact that CS1 cleav-
age is required for efficient replication is interesting for several
reasons. CS1 is conserved in group 1 and 2 coronaviruses but
not in group 3 coronavirus (IBV), suggesting that either intro-
duction or retention of CS1 is critical to the replication or
pathogenesis of these viruses (27). The ability of the virus to
survive abolition of the cleavage site suggests that the cleavage
site may have evolved after fundamental proteins and func-
tions. If this is so, then the genetic experiments in this study
may have recapitulated an earlier stage of coronavirus evolu-
tion in which group 1, 2, and 3 coronaviruses may have had in
common more expression and possibly functional characteris-
tics in the amino-terminal replicase proteins. Moreover, the
possibility that cleavage sites evolved after protein function
suggests that the 93-kDa uncleaved precursor resulting from
inhibition at CS1 could serve functions similar to those of the
p87 protein of the group 3 coronavirus IBV, which does not
undergo further processing during IBV replication. However,
no 93-kDa p28-p65 precursor has ever been detected in MHV-
infected cells, with cleavage at CS1 clearly demonstrated to be
an early, rapid, cotranslational event both in in vitro translation
studies and during virus infection, suggesting an early regula-
tory process (9). In addition, there is no amino acid identity,
similarity, or predicted structural similarity (data not shown)
between IBV p87 and the engineered MHV p93 protein, sug-
gesting that these are in fact different proteins. Generation of
chimeric viruses in the 5 end of the replicase gene would likely
be necessary to determine any functional similarities in these
proteins. In summary, all of the data support the conclusion
that MHV has carefully orchestrated the separation of p28
from p65 at CS1 as the first step after initiation of replicase
polyprotein translation.
Noncleaving CS1 mutants have defects in viral growth and
RNA synthesis: implications for p28 and p65 functions. The
effects of mutations at CS1 on viral replication suggest possible
FIG. 6. Growth and protein expression of CS1 deletion mutant mutCS1. (A) Viral growth. Following infection at an MOI of 0.1 PFU/cell,
virus growth was determined by plaque assay as described in the legend to Fig. 4 for the viruses indicated in the inset. mut indicates mutCS1
throughout the figure. p.i., postinfection. (B) Protein expression. DBT cells were infected for 6 h and labeled with [35S]Met-Cys for 60 min, and
lysates of infected cells were immunoprecipitated with UP102, followed by electrophoresis on sodium dodecyl sulfate–5 to 18% polyacrylamide
gels. Molecular mass markers are to the left of the gel, and specific products are to the right (masses are in kilodaltons). Viruses are indicated above
the lanes. mut indicates mutCS1. *mut is the same gel lane as mut but exposed to film four times as long as the other lanes. (C) Lysates from
panel B immunoprecipitated with -p22 antiserum. A marker protein is shown to the left, and the location of p22 is shown to the right of the gel.
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functional roles for p28 and p65 in the MHV life cycle. Previ-
ous cell imaging and biochemical results have indicated that
p28 and p65 may function during viral RNA synthesis. Specif-
ically, both p28 and p65 localize to replication complexes and
are associated with the same membranous complex as the
putative RdRp (Pol) protein (4, 20; Brockway et al., submit-
ted). It is clear from the results of this report that separation of
p28 from p65 likely contributes to optimal RNA synthesis and
virus growth. If p28 and p65 are integral components of viral
replication complexes, how is MHV able to survive such a
profound alteration in the expression of these proteins caused
by abolition of CS1 cleavage? The most straightforward expla-
nation is that the functions of p28 and/or p65 are partially
retained in the uncleaved p28-p65 precursor (p93). In this
model, the demonstrated inhibition of virus growth and RNA
synthesis in the noncleaving mutants could be due to alter-
ations in membrane or protein interactions, intracellular local-
ization, or possible altered conformation of the p28 or p65
domain within p93. In essence, the defects in virus growth
could be due either to a single population of p93 performing
both p28 and p65 functions at suboptimal levels or to an ap-
portioning of the p93 protein into two populations: one per-
forming the function(s) of p28 and the other fulfilling the
functional requirements of p65.
Another possibility is that an alternative cleavage of the
93-kDa precursor could generate proteins capable of at least
the minimal activity required for virus replication. The heter-
ogeneous 70-kDa product was detected by immunoprecipi-
tation with UP102 (anti-p28 and -p65) from all of the CS1-
noncleaving mutants, including mutCS1. Since CS2 was
efficiently cleaved in these mutants, a p70 protein would most
likely be produced by a cleavage upstream of CS1 in the
polyprotein. It is interesting in this regard that MHV contains
a Gly-Ala dipeptide upstream of CS1 in the p28 domain, which
would produce an 70-kDa protein if cleaved (data not
shown). Further, such a cleavage would result in proteins of 20
and 70 kDa, which are similar to the predicted sizes of nsp1
and nsp2 of SARS-CoV. Thus, an alternative 70-kDa protein
might at least partially compensate for p65 function. However,
if this is normally an unused site, then it is also possible that
such a protein is not preferred by the virus and that an alter-
native cleavage product might actually function in a dominant-
negative fashion, thus contributing to the RNA synthesis and
growth defects in mut3, mut4, mut5, and mutCS1. Studies to
determine the possibility of such an alternative cleavage event,
as well as possible requirements within the coding sequences of
p28 and p65 necessary to allow such an event, will be the focus
of a future study.
Processing determinants within CS1 and stability of muta-
tions. Our results confirmed and extended the previously pub-
lished in vitro results (10, 14) by demonstrating that substitu-
tions at P2-R246 and P1-G247 abolished cleavage at CS1, while
in contrast, P1-V248 could be replaced with both small non-
charged residues, such as Ala, and with bulkier charged resi-
dues, such as His, and still retain complete CS1 cleavage. Thus,
the requirements for P2 and P1 appear to be strict, whereas P1
appears quite tolerant of substitutions. Furthermore, the re-
covery of mutant viruses with P2-P1 deleted (mutCS1) dem-
onstrated that substantial changes are tolerated within P2-P1
of CS1. When mutant viruses were passed in culture under
conditions to select for more rapid replication and CPE, no
changes were noted in the replication phenotype of the virus by
growth, CPE, or plaque morphology, and sequence compari-
son of the “parental” and passaged viruses identified no pri-
mary- or secondary-site changes within the first 5 kb of gene
1. It is possible that the growth defect in the CS1-noncleaving
mutants of a 0.5- to 1.5-log reduction in the peak titer was not
enough to allow the emergence of revertants over the passages
in this experiment. Increased selective pressure, such as tem-
perature changes or the presence of proteinase inhibitors, may
be required to further drive down the replication of the non-
cleaving mutants and favor selection for viruses with compen-
sating mutations. Another possibility is that there may be
unique constraints on changes to the nucleotides or amino
acids at and flanking the cleavage sites, or more broadly in the
5 5 kb of the RNA genome. At the protein level, the deter-
minants for CS1 cleavage may be so local (P5 through P1) that
more distal mutations cannot compensate for the strict re-
FIG. 7. RNA synthesis in CS1 mutants. (A) Metabolic labeling of
viral RNA. DBT cells were mock infected (M) or infected with A59,
icwt, or the indicated CS1 mutants. At 4.5 hpi, actinomycin D was
added to a final concentration of 20 g/ml. Cells were radiolabeled
with [3H]uridine from 5 to 7 hpi and lysed, and TCA-precipitated viral
RNA was quantitated by liquid scintillation counting. Error bars rep-
resent standard deviations of duplicate measurements. mut indicates
mutCS1 throughout the figure. (B) Northern blot analysis. DBT cells
were mock infected or infected with A59, icwt, or the indicated CS1
mutants in parallel with the infections shown in panel A. Cells were
lysed in Trizol at 10 hpi, and RNA from approximately 4  105 cells
was separated on a 0.8% agarose-formaldehyde gel. RNA was trans-
ferred to a nylon membrane, UV cross-linked, and probed with a 32P-
labeled negative-polarity primer complementary to the 3 UTR to de-
tect positive-strand RNA species. Top, 6-h exposure of genomic RNA
(RNA 1); bottom, 1-h exposure of all positive-strand RNA species.
Genomic RNA and sgRNA species are indicated by number to the right.
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quirements for recognition and cleavage of CS1. If the viruses
retain their RNA synthesis and growth phenotype over ex-
tended passage or under increased pressure for reversion, it
will be important to sequence the entire genome of one or
more of these viruses to determine whether changes in down-
stream replicase, accessory, or structural proteins can compen-
sate for the introduced changes.
In conclusion, we have engineered and established mutant
viruses that either allow or abolish cleavage between p28 and
p65 at CS1. These viruses maintain their introduced mutations
and growth phenotypes upon repeated passage in culture, de-
spite defects at the levels of RNA synthesis and viral titer,
suggesting that there may be significant genetic stability of
viable cleavage site mutants. These viruses provide a panel of
mutants with distinct phenotypes in growth, RNA synthesis,
and protein processing, but the viruses are readily grown and
analyzed in culture. Thus, they will provide powerful models
for determination of the roles of p28 and p65 in replication
complex formation and RNA synthesis. Further, the viruses
will form the basis for studies of the functions and require-
ments of PLP1 and PLP2 function during replication. Since
the engineered defects are localized to p28 and p65, it will
be possible to determine which of the proteins is responsible
for the defect or if it results from the unique fusion of the
proteins. Finally, they will form the basis for studies of repli-
case proteins in viral pathogenesis and in possible mechanisms
of attenuation of replication and virulence that might be
broadly applicable to studies of animal and human coronavi-
ruses.
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